Castle Biosciences Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Für Castle Biosciences wird ein Gewinn- und Umsatzwachstum von 41.3% bzw. 8.7% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 35.3% pro Jahr steigen soll.
Wichtige Informationen
41.3%
Wachstumsrate der Gewinne
35.30%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 18.4% |
| Wachstumsrate der Einnahmen | 8.7% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 13 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Apr 22
CSTL: 2026 Clinical Data And Guidance Will Support Higher Confidence
Analysts have trimmed their modeled fair value for Castle Biosciences to $47.25 from $48.50 as they recalibrate long term revenue growth, profit margin, and future P/E assumptions following a mix of recent price target increases and a reduction from different research firms. Analyst Commentary Bullish Takeaways Bullish analysts who raised their price targets highlight room for upside in their models, which typically reflects confidence in the company’s ability to execute on its current pipeline and commercial plans.Narrativ-Update • Apr 04
CSTL: Preliminary 2025 Update Will Support Higher Confidence In 2026 Revenue
Analysts have lifted their price targets on Castle Biosciences by up to $17, reflecting updated models that now reference 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent price target changes cluster around updated 2026 revenue frameworks and the company’s preliminary 2025 revenue disclosure.Seeking Alpha • Mar 30
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Summary Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable growth driver with high clinical utility, workflow integration, and payer support, targeting a large and growing melanoma market. I assign CSTL a conviction rating of 3/5, initiating a pilot position near technical support, with plans to build exposure as the market digests 2026 earnings and product adoption. Read the full article on Seeking AlphaNarrativ-Update • Mar 20
CSTL: Preliminary 2025 Revenue Signals Stronger Confidence In 2026 Outlook
Analysts have lifted their price targets on Castle Biosciences by amounts ranging up to $17, pointing to updated revenue estimates through 2026 and recent preliminary 2025 revenue disclosures as key drivers of their revised outlooks. Analyst Commentary Recent research notes focus on how preliminary 2025 revenue disclosures and updated 2026 revenue estimates feed into Castle Biosciences' valuation, with several firms adjusting their price targets to reflect these updated assumptions.Narrativ-Update • Mar 06
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have modestly adjusted their fair value estimate for Castle Biosciences to $48.50, citing updated revenue growth and profit margin assumptions, as well as a slightly lower future P/E multiple, as reflected in recent price target increases from several firms. Analyst Commentary Recent research updates on Castle Biosciences have centered on revised revenue assumptions for 2025 and beyond, along with higher price targets that feed into the updated fair value estimate of $48.50.Narrativ-Update • Feb 20
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have raised their average price target on Castle Biosciences by $14, citing updated models that now rely more on 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent research updates on Castle Biosciences focus heavily on how preliminary 2025 revenue information feeds into 2026 models, which in turn support higher price targets.Narrativ-Update • Feb 05
CSTL: Preliminary 2025 Revenue Signals Will Support Extended 2026 Upside Potential
Narrative Update The updated analyst price target for Castle Biosciences moves from $46.00 to about $48.57. Analysts point to refreshed assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change.Narrativ-Update • Jan 21
CSTL: Extended 2026 Revenue View And Test Adoption Will Support Upside
Narrative Update: Castle Biosciences Analysts have lifted their fair value estimate for Castle Biosciences from US$42.50 to US$46.00, citing updated modeling that now anchors price targets on 2026 revenue expectations following preliminary 2025 revenue disclosures. Analyst Commentary Recent Street commentary around Castle Biosciences is centering on how the preliminary 2025 revenue update reshapes expectations and valuation anchors out to 2026.Narrativ-Update • Jan 06
CSTL: Dermatology Test Adoption And New Launches Will Support Balanced Outlook
Analysts have lifted their price target on Castle Biosciences from US$38.75 to US$42.50, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News New data from a prospective multicenter study comparing NGS-based mutation analysis with the combination of DecisionDx-UM and PRAME for uveal melanoma outcomes was published in Nature Communications, with DecisionDx-UM described as widely adopted in the U.S. standard of care and included in AJCC and NCCN guidelines (Key Developments).Narrativ-Update • Dec 13
CSTL: Broader Dermatology Test Adoption Will Support Balanced Long-Term Outlook
Analysts have raised their price target on Castle Biosciences to approximately 38.75 dollars from about 35.63 dollars, citing stronger expectations for revenue growth and slightly improved profit margins, despite a modestly higher discount rate and lower projected future P E multiple. What's in the News An independent expert consensus panel endorsed Castle Biosciences DecisionDx-Melanoma test as providing robust, clinically validated prognostic information that improves melanoma risk stratification and supports more precise treatment decisions (expert consensus paper).Analyseartikel • Nov 06
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up
Despite an already strong run, Castle Biosciences, Inc. ( NASDAQ:CSTL ) shares have been powering on, with a gain of...Analyseartikel • Aug 24
What Castle Biosciences, Inc.'s (NASDAQ:CSTL) 30% Share Price Gain Is Not Telling You
The Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has done very well over the last month, posting an excellent...Analyseartikel • Jun 28
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • May 23
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28%
Unfortunately for some shareholders, the Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has dived 28% in the last...Analyseartikel • Apr 16
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)?
While Castle Biosciences, Inc. ( NASDAQ:CSTL ) might not have the largest market cap around , it saw a double-digit...Seeking Alpha • Apr 14
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
Summary Castle Biosciences offers diverse diagnostic tests, with DecisionDx-Melanoma being a key revenue driver, but faces potential Medicare reimbursement loss for DecisionDx-SCC in 2025. The company is expanding its portfolio with TissueCypher and IDgenetix, showing strong growth, though IDgenetix faces uncertain long-term performance. Castle is well capitalized with $293 million in cash, providing a strong runway, but continues to burn cash, mainly on general and admin expenses. Trading near 52-week lows, CSTL stock presents a good entry point, but investors should watch for clarity on the SCC non-coverage issue. Read the full article on Seeking AlphaAnalyseartikel • Feb 25
Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
Neues Narrativ • Feb 13
Positive Clinical Adoption Of DecisionDx Tests Will Strengthen Future Market Position
Strong revenue growth driven by increased adoption of DecisionDx tests and promising market expansion suggests potential for significant future earnings.Analyseartikel • Dec 12
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Oct 15
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Key Insights The projected fair value for Castle Biosciences is US$66.66 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Aug 16
Castle Biosciences: Inflection Into Profitability
Summary Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. Castle Biosciences faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field. Read the full article on Seeking AlphaAnalyseartikel • Aug 11
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Celebrations may be in order for Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders, with the analysts delivering a...Analyseartikel • Aug 08
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders of Castle Biosciences, Inc. ( NASDAQ:CSTL ) will be pleased this week, given that the stock price is up...Analyseartikel • Aug 04
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders are no doubt pleased to see that the share price has bounced 28...Analyseartikel • Jul 12
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Analyseartikel • Jan 27
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Castle Biosciences, Inc.'s ( NASDAQ:CSTL ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 435 | -11 | 31 | 72 | 5 |
| 12/31/2027 | 393 | -25 | 16 | 43 | 8 |
| 12/31/2026 | 352 | -42 | -22 | 8 | 8 |
| 3/31/2026 | 340 | -13 | 5 | 48 | N/A |
| 12/31/2025 | 344 | -24 | 28 | 64 | N/A |
| 9/30/2025 | 344 | -12 | 25 | 62 | N/A |
| 6/30/2025 | 346 | -9 | 35 | 62 | N/A |
| 3/31/2025 | 347 | -5 | 42 | 66 | N/A |
| 12/31/2024 | 332 | 18 | 37 | 65 | N/A |
| 9/30/2024 | 312 | 6 | 35 | 59 | N/A |
| 6/30/2024 | 288 | -3 | 20 | 41 | N/A |
| 3/31/2024 | 251 | -31 | -6 | 13 | N/A |
| 12/31/2023 | 220 | -57 | -19 | -6 | N/A |
| 9/30/2023 | 192 | -76 | -42 | -30 | N/A |
| 6/30/2023 | 168 | -89 | -52 | -40 | N/A |
| 3/31/2023 | 152 | -72 | -54 | -46 | N/A |
| 12/31/2022 | 137 | -67 | -47 | -42 | N/A |
| 9/30/2022 | 124 | -53 | -43 | -38 | N/A |
| 6/30/2022 | 110 | -44 | -43 | -39 | N/A |
| 3/31/2022 | 98 | -52 | -40 | -37 | N/A |
| 12/31/2021 | 94 | -31 | -22 | -19 | N/A |
| 9/30/2021 | 86 | -30 | -20 | -17 | N/A |
| 6/30/2021 | 78 | -23 | -18 | -13 | N/A |
| 3/31/2021 | 68 | -15 | 1 | 6 | N/A |
| 12/31/2020 | 63 | -10 | 5 | 10 | N/A |
| 9/30/2020 | 63 | -3 | 10 | 15 | N/A |
| 6/30/2020 | 63 | 7 | 16 | 18 | N/A |
| 3/31/2020 | 61 | 6 | 4 | 5 | N/A |
| 12/31/2019 | 52 | 3 | N/A | 7 | N/A |
| 9/30/2019 | 46 | 4 | N/A | -1 | N/A |
| 6/30/2019 | 35 | -6 | N/A | -3 | N/A |
| 3/31/2019 | 28 | -8 | N/A | -8 | N/A |
| 12/31/2018 | 23 | -10 | N/A | -12 | N/A |
| 12/31/2017 | 41 | -46 | N/A | -37 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CSTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: CSTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: CSTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: CSTLDie Einnahmen des Unternehmens (8.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: CSTLDie Einnahmen des Unternehmens (8.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CSTL in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/24 03:16 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Castle Biosciences, Inc. wird von 9 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |